A c c e p t e d m a n u s c r i p t
Introduction
Mitochondrial diseases impairing oxidative phosphorylation (OXPHOS) can affect multiple organs or single ones and can be caused by mutations in nuclear genes or in the mitochondrial DNA (mtDNA). Mutations in mtDNA are commonly in a heteroplasmic state, where mutant mtDNA co-exists with wild-type. There are approximately 1,000 mtDNA molecules in a cell, and the wild-type mtDNA can compensate for the presence of mutant mtDNA, up to threshold levels, which are usually relatively high, 70-95% [1] [2] [3] . This "recessive" feature of the mutant mtDNA means that by simply reducing the relative levels of mutant mitochondrial genomes, biochemical defects can be reversed.
TALENs are engineered nucleases based on the TALE DNA-binding domain from Xanthomonas fused to a FokI type-II nuclease domain. Because the FokI domains need to dimerize to cleave DNA, two TALEN monomers are required to bind adjacent recognition sequences on opposing sense/antisense strands of DNA [4, 5] . The DNA binding specificity of TALE domains is given by tandem copies of 34 amino acid repeats that each preferentially bind one of the four DNA bases depending on the amino acids at positions 12 and 13 of the repeat. The nucleotide affinity of these Repeat Variable Di-residues (RVDs) is well understood, providing the basis to engineer novel specificities [6, 7] . Because the last repeat contains only 20 amino acids (instead of 34) , it is referred to as a 0.5 repeat.
Commonly, 15.5-22.5 TALE repeats are used per monomer to avoid off-target cleavage [5, 8] .
Although TALEN can be very specific for genetic loci, this specificity is not perfect and off-site cleavages, in large and complex genomes, are a concern [9] . Moreover, as mentioned above, the high specificity of TALENs is in great part due to the combination of both sequence specificity of TALE binding and the positional requirements of FokI cleavage. In this context, the ability of TALENs to differentiate targets with only single nucleotide differences is difficult.
We have previously shown that for at least one point mutation (m.14459A>G), mitochondrialtargeted TALEN (mitoTALEN) was able to reduce the mutation load [10] . This is compatible with our previous observation that the mutant mtDNA undergoing a double-strand break by restriction A c c e p t e d m a n u s c r i p t endonucleases is followed by rapid degradation [11] . The mtDNA copy number control ensures that the residual (wild-type) intact mitochondrial genomes re-populate the cell [12] .
To test whether expression of mitoTALEN could be a general approach for the reduction of the levels of mtDNA point mutations, we developed mitoTALENs for two relatively common pathogenic mtDNA mutations. One is the m.8344A>G mutation in the tRNA lysine gene that accounts for 80 to 90% of cases presenting with Myoclonus Epilepsy with Ragged Red Fibers (MERRF) syndrome [13, 14] and the other is the m.13513G>A mutation in the ND5 gene associated with MELAS/Leigh syndrome [15] [16] [17] . We have also explored the reduction of the size of the mitoTALEN monomers to optimize their use for gene therapy.
Results

Designing mitoTALENs
We developed TALENs against two distinct mtDNA point mutations at positions m.8344A>G and m.13513G>A (Fig. 1) . A required element for the binding of the N-terminus of most TALEN monomers is a T at position 0 in the DNA recognition sequence, immediately upstream (5') to the region recognized by the RVDs [4, 7] . MtDNA has a well-recognized transition bias for naturally occurring point mutations (>90% transitions vs transversions [18] ). For C>T and G>A "gain of T" transition mutations the requirement for T 0 can be exploited to develop TALENs that can differentially recognize and cleave these mutations, as we have demonstrated in one previous case [10] . For the m.13513G>A mutation in ND5 we further explored the utility of this approach, designing two different TALENs where the differentiating monomer binding site included a T 0 of the antisense strand at the G>A mutation ( Fig. 1b and Supplementary Fig. S1 ). The two TALENs differed from each other by the numbers of RVD repeats for the monomer binding the mutation, one having 9.5 RVDs and the other 12.5 RVDs.
A c c e p t e d m a n u s c r i p t
Unfortunately, the m.8344A>G mutation does not allow for the use of T 0 design strategy as it is a T>C, A>G mutation, i.e. "loss of T". In the sense strand, the transition A>G posed a further challenge for the design, as the conventional RVD for binding G is "NN" which cannot discriminate between A and G effectively [4, 7] , which constitute the wild-type and mutant alleles for this mutation. However, in the anti-sense strand, the mutant gains a C, which can be recognized more specifically by an "HD" RVD that does not effectively bind T (the base present in the wild type antisense). Therefore, for m.8344A>G, we chose to place the mutated G at position 3 of the antisense monomer, exploiting a "gain of C3" model ( Fig. 1b) . We developed two m.8344A>G TALEN pairs with this general design, the main difference being that the monomer binding the mutated region had either 9.5 RVDs or 15.5 RVDs ( Supplementary Fig. S1 ). In both of them we designed the DNA binding domain to include the mutant G at position C3 of the antisense strand ( Fig. 1 and Supplementary Fig. S1 ). These TALENs were initially tested in yeast Single-Strand Annealing assays. Because one of the pairs (version A) showed similar efficiency in the binding and cleavage of both mutant and wild-type target sequences ( Supplementary   Fig. S2 ), it was not used further and the subsequent experiments were performed with version B only ( Fig. 1 and S2 ).
For all TALENs the obligate heterodimeric FokI nuclease domains were used to reduce self-self offsite cleavage [19] [20] [21] . Monomers were re-engineered to contain a mitochondrial localization signal (MLS, from SOD2 or COX8A/Su9), a specific immunological tag (HA or FLAG), a poly(A)/3' UTR (SOD2 or ATP5B), and a fluorescent marker (mCherry or eGFP), the latter being separated from the TALEN coding region by a T2A picornavirus ribosome stuttering sequence [10, 22] . Mitochondrial localization was verified by immunocytochemistry (Fig. 2) . The presence of full-length proteins was determined by western blots (Fig. 2) . Some of the monomers showed two bands in western blots, and mitochondrial isolation and treatment with proteinase K indicates that the higher MW band corresponds to a small fraction of the monomer harboring the COX8A/Su9 that remains attached to the outside of the mitochondria ( Supplementary Fig. S3 ). Nonetheless, the mtDNA heteroplasmy changes (described A c c e p t e d m a n u s c r i p t below) show that the MLS are able to localize the mitoTALENs in the mitochondrial matrix with access to the mtDNA.
mitoTALENs promote a robust change in mtDNA heteroplasmy.
To test the efficacy of the mitoTALENs we produced transmitochondrial cybrid cell lines harboring different levels of the respective heteroplasmic mtDNA point mutations [23, 24] . Selected cybrid lines with a high level of mutant mtDNA were transfected with pairs of plasmids coding for each mitoTALEN monomer. Two days after transfection, cells were sorted for the fluorescent markers (mCherry and eGFP), and analyzed. Borrowing from the color effects seen in overlay images, cells expressing both green (eGFP) and red (mCherry) markers were termed "Yellow", and cells sorted as negative for the markers were termed "Black" (Supplementary Fig. S4 ). Most of subsequent experiments herein compare Yellow and Black cell populations. Fig. 3a shows that the m.8344A>G mitoTALEN was able to markedly reduce the levels of mutant mtDNA in Yellow cells.
Sorted cells were also cultured long term and we found that the robust change in mtDNA heteroplasmy levels in transmitochondrial cybrids (Fig. 3a) , which was maintained over time (Fig. 3b ).
This finding is consistent with our previous study [10] . We did notice a slight drift towards increasing wild-type mtDNA levels over time, including in the Black cell population (Fig. 3b) . We believe that the Black cell population may contain low levels of transfected cells and some cleavage of the mutant mtDNA may have occurred at low levels.
Both the 9.5 and 12.5 RVD mitoTALENs against the m.13513G>A mutation triggered a robust shift in heteroplasmy. Fig. 3c illustrates the heteroplasmy shift obtained with one of them (version B) and shows the quantitative determinations for both mitoTALEN versions. (Fig. 4a) . The m.8344A>G mutation in tRNA Lys is known to impair mitochondrial translation due to its defective aminoacylation [25] . We measured the steady-state levels of two OXPHOS proteins: 1) NDUFB8, a nuclear encoded subunit of Complex I and 2) COXI, an mtDNA-coded subunit of Complex IV. Because the protein synthesis defect is relatively mild in heteroplasmic cells, we included low concentrations of the mitochondrial protein synthesis inhibitor doxycycline (DOX) to stress the defect. As shown in Fig. 4b , the levels of these proteins were decreased at lower concentrations of DOX in untransfected cells. Although NDUFB8 is nuclear encoded, the steady-state levels of this protein are reduced because it is rapidly degraded if not incorporated into the final complex I assembly [26] . Finally, we measured the activity of Complex IV, and found that Yellow cells had a significant increase in Complex IV activity (Fig. 4c ).
Similar results were obtained for when transfecting the m.13531G>A ND5 heteroplasmic cybrid cells with our mitoTALEN. Yellow cells respired more robustly ( Fig. 5a ) and had restored Complex I activity ( Fig. 5b ) when compared to the parental cell line harboring the m.13531G>A mutation in ND5, which impairs complex I activity and respiration [16, 17] . As expected, there was no change in complex IV activity in Yellow cells ( Fig. 5c ) because ND5 is a subunit of Complex I.
Optimizing mitoTALENs for gene therapy
Although mitoTALENs are promising tools for the genetic therapy of patients with heteroplasmic mtDNA mutations, some challenges remain. A technical one is related to the large size of mitoTALENs and the requirement for two monomers that make it difficult to package them in many vector systems. Because mtDNA is a low complexity genome compared to the nuclear genome, we and 7.5 RVDs) was perhaps the least robust, with more variability among independent experiments, but was still able to significantly eliminate mutant mitochondrial genomes (Fig. 6 ).
Discussion
Through these experiments we were able to establish mitoTALEN as a general approach to reduce point mutant mtDNA loads in a heteroplasmic environment. We were able to reduce the mutation load in cultured cells harboring two clinically-important mtDNA mutations that cause severe encephalopathies. The elimination of the target mutant mtDNA was not complete, and we do not have an explanation for that. Mitochondrial-targeted restriction endonucleases gave us a more robust elimination of the targeted mitochondrial genome [27] , suggesting that mitoTALENs are less efficient than restriction nucleases to cleave the mtDNA. Although the TALEN architecture involves specific binding to 30-40 bases (15-20 per monomer) in most cases [4] , the low mtDNA complexity allowed us to reduce the binding site down to a total of 17 bases. It appears particularly important to make the binding site to the mutated region small, thereby increasing the impact of a single base change. This was illustrated by the fact that the m.8344A>G mitoTALEN version A, which had the monomer binding to A c c e p t e d m a n u s c r i p t the mutation harboring 15.5 RVDs, was unable to differentiate mutant and wild-type targets. On the other hand, monomers with ≤12.5 RVDs appear to be able to discriminate single base differences.
However, it is important to emphasize that the location of the discriminating base has a major impact on the binding. The importance of binding at different positions of TALEN monomers has been the subject of many studies [4, 28] , and it is generally accepted that the proximal bases have a higher impact on binding [29] . The presence of a T at position 0 is a required feature for most TALEN architectures, although in some cases a C at this position was reported as permissible to binding [4] , and, different specificities for N-terminus binding are being developed [30] . Therefore, whenever possible, we took advantage of position T0 as the discriminating one. However, as exemplified by the m.8344A>G mutation, this is not always possible. In this particular mutation, we were able to place a C at position 3 and found that it was able to effectively discriminate between mutant and wild-type mtDNA. However, as mentioned above, this was true only when the mitoTALEN monomer binding to the m.8344A>G Although the reduction in size will facilitate technical issues related to vector design, alternative architectures, such as zinc finger nucleases (ZFN) that are intrinsically shorter, could also be used [32] .
In our hands ZFN are more complex to design and modify although it is an architecture also shown to work in reducing mtDNA heteroplasmy [33, 34] . 
Material and Methods
MitoTALEN constructs.
Custom-made TALE domains were assembled by Cellectis Bioresearch (Paris, France). We designed and constructed plasmids coding for mitoTALEN monomers using the In-Fusion HD cloning kit from Clontech Laboratories according to Bacman et al [10] . Modifications included removal of the nuclear localization signal, inclusion of a mitochondrial localization signal derived from SOD2 or modified COX8A/Su9 tandem MLS, inclusion of a unique immuno-tag in the N terminus of the mature A c c e p t e d m a n u s c r i p t protein (Hemagglutinin (HA) or Flag), inclusion of a 3′ untranslated region from a mitochondrial gene known to localize mRNA to ribosomes on mitochondria, inclusion of an independent fluorescent marker to select for expression (eGFP in one monomer and mCherry in the other) and inclusion of a recoded picornaviral 2A-like sequence (T2A) between the mitoTALEN and the fluorescent marker [10, 22] .
Single-strand annealing (SSA assay).
Single-strand annealing in Saccharomyces cerevisiae was performed as previously described [35] .
Cells, transfection and sorting.
Heteroplasmic cybrids harboring the m.8344A>G/tRNA 
Mitochondrial expression of the mitoTALENs
For western blot studies, we subjected 40 µg of total proteins from cellular homogenates of COS7 cells collected 48 h after transfection to electrophoresis in 4-20% Tris-HCl polyacrylamide gels (4561094; Bio-Rad Laboratories) and transferred the separated proteins to nitrocellulose membranes
A c c e p t e d m a n u s c r i p t
(162-0115, Bio-Rad), as described [27] . Antibodies used for blotting were rat monoclonal antibody to 
Sequencing
Samples were sequenced using ABI BigDye chemistry according to manufacturer's procedure.
Sequences were aligned using CLCBio Main Workbench (Qiagen). 
A c c e p t e d m a n u s c r i p t OXPHOS proteins expression under doxycycline treatment
Enzyme activities.
For spectrophotometric analysis, we subjected 9 × 
Statistical analyses.
Pairwise comparisons were performed using two-tailed Student's t-test using GraphPad Prism (GraphPad Software, Inc.) and SPSS package (v.22, IBM). ANOVA was performed with SPSS.
Acknowledgments
We are grateful to the skilled assistance of the Flow Cytometry Core Facility for the cell sorting A c c e p t e d m a n u s c r i p t RVDs=92.5KDa; m.13513G>A-15.5 RVDs=102.5KDa; m.13513G>A-9.5 RVDs=92.5KDa.
Normalization was done with monoclonal actin antibody.
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